Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
CytoDyn, Inc. clinical trials
The registry lists 24 studies whose lead sponsor is CytoDyn, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 9, 2026.
Keep track of what changes. Save the CytoDyn, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to CytoDyn, Inc..
- CytoDyn, Inc.24 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 24 of 24.
- An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)AvailableNCT07536815
- CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenActive, not recruitingNCT06699836Phase 2
- Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionCompletedNCT02859961Phase 2/3
- Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid TumorsCompletedNCT04504942Phase 2
- An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyTerminatedNCT02990858Phase 2/3
- An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyTerminatedNCT05271370Phase 2/3
- Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19CompletedNCT04347239Phase 2
- An Extension of Protocol PRO 140_CD01 StudyTerminatedNCT02355184Phase 2
- PRO 140 in Treatment-Experienced HIV-1 SubjectsCompletedNCT03902522Phase 2/3
- Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCTerminatedNCT03838367Phase 1/2
- A Compassionate Use Study of Leronlimab in Breast CancerNo longer availableNCT04313075
- Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19CompletedNCT04678830Phase 2
- A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationTerminatedNCT02737306Phase 2
- Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 InfectionCompletedNCT02175680Phase 2
- Safety and Tolerability of PRO 140 in HIV Uninfected Male VolunteersCompletedNCT00110591Phase 1
- Leronlimab (PRO 140) in Patients With Nonalcoholic SteatohepatitisCompletedNCT04521114Phase 2
- Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal CancerWithdrawnNCT05730673Phase 2
- Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19CompletedNCT04343651Phase 2
- Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140CompletedNCT02483078Phase 2/3
- An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 StudyNo longer availableNCT02759042
- A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor AdherenceWithdrawnNCT01272258Phase 2
- PRO 140 by IV Administration in Adults With HIV-1 InfectionCompletedNCT00613379Phase 2
- Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 InfectionCompletedNCT00642707Phase 2
- Observational Study of Blood Treated With CytolinCompletedNCT01048372